Despite a narrowly negative advisory panel vote, the FDA approved UroGen Pharma’s intravesical hydrogel treatment, Zusduri (mitomycin), for low-grade, intermediate-risk non-muscle invasive bladder cancer. Clinical trial data demonstrated a 78% complete response at three months, sustaining most responses at 12 months. The hydrogel offers a nonsurgical option to reduce the recurrence of bladder tumors and plans for U.S. availability are set for July 2025.